Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03575364 · ClinicalTrials.gov registry record
ClotTriever Outcomes (CLOUT) Registry
A clinical trial, sponsored by Inari Medical.
- Completed
- Registry status
- 499
- Enrollment target
NCT03575364: Completed study, sponsored by Inari Medical.
NCT03575364 is a clinical trial that has completed, run by Inari Medical. The registered enrollment target is 499 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03575364 has completed, sponsored by Inari Medical.
- COMPLETED
- Registry status
- 499 participants
- Enrollment target
Study Summary
Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
Primary Outcome
The primary safety endpoint is the proportion of participants with Major Adverse Events (MAE). MAEs are defined as a composite endpoint triggered when any of four categories of events occurred through 30 days after the index procedure, as observed in the Primary Safety Cohort (the composite endpoints were not observed for the Full Analysis Population: * All-cause mortality * Major bleeding * New symptomatic pulmonary embolism (PE) documented by computed tomography pulmonary angiography (CTPA) *
Interventions
- DEVICE ClotTriever
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 499 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2024-07-02 |
What the finished NCT03575364 record still lists
NCT03575364 is an observational study that tracks outcomes without assigning an intervention. The registered 499 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ClotTriever is the first listed.
NCT03575364 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03575364 about?
NCT03575364 is a clinical study titled "ClotTriever Outcomes (CLOUT) Registry". Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
What is the current status of trial NCT03575364?
This trial is currently completed. The enrollment target is 499 participants. The study started on 2018-09-01. Estimated completion is 2024-07-02.
What interventions are being tested in trial NCT03575364?
The interventions under investigation include: ClotTriever (DEVICE).
Who is sponsoring clinical trial NCT03575364?
This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI